Basically, the most important problem I see in terms of diagnosing inflammatory myopathies is the fact that we can miss them, and those are treatable conditions. So the first part of my talk that is expected to be on Monday is basically to make clinicians aware of this condition first and be able to differentiate it from the non-treatable conditions. I have in mind one example, which is also part of the inflammatory myopathies, is the sporadic inclusion body myositis, so IBM...
Basically, the most important problem I see in terms of diagnosing inflammatory myopathies is the fact that we can miss them, and those are treatable conditions. So the first part of my talk that is expected to be on Monday is basically to make clinicians aware of this condition first and be able to differentiate it from the non-treatable conditions. I have in mind one example, which is also part of the inflammatory myopathies, is the sporadic inclusion body myositis, so IBM. This one is non-treatable, while the other inflammatory myopathies are treatable with immunosuppressive drugs. So dividing this and making the difference between those two is really important.
You need to start first with the anamnesis, that’s really important, and then the clinical examination is really important as well. For sporadic IBM, basically there are key clinical features such as finger flexors and quadriceps weakness, and if you spot that in the patient, you can even do the diagnosis like that without requiring any other MRI or electromyography, etc. On the other hand, with the inflammatory myopathies that are treatable, it’s more like a proximal weakness that is usually symmetric with high CK levels. So of course you need then to use additional diagnostic tools such as MRI, antibody testing, and EMG, and eventually muscle biopsy as well to be sure of your diagnosis and to separate these entities and to be sure that you are treating inflammatory myopathies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
